Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer

• Published in: Frontiers in immunology 2023-02, Vol.14, p.1122352-1122352
• Main Authors: Jie, Chen, Li, Rumeng, Cheng, Yajie, Wang, Zhihao, Wu, Qiuji, Xie, Conghua
• Format: Article
• Language: English
• Subjects: Carcinoma, Non-Small-Cell Lung; DMNTis; DNA; Feasibility Studies; Humans; Immunology; Immunotherapy; Lung Neoplasms; Methyltransferases; NSCLC; radiotherapy; synergistic effect
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1122352

The morbidity and mortality of lung cancer are increasing, seriously threatening human health and life. Non-small cell lung cancer (NSCLC) has an insidious onset and is not easy to be diagnosed in its early stage. Distant metastasis often occurs and the prognosis is poor. Radiotherapy (RT) combined with immunotherapy, especially with immune checkpoint inhibitors (ICIs), has become the focus of research in NSCLC. The efficacy of immunoradiotherapy (iRT) is promising, but further optimization is necessary. DNA methylation has been involved in immune escape and radioresistance, and becomes a game changer in iRT. In this review, we focused on the regulation of DNA methylation on ICIs treatment resistance and radioresistance in NSCLC and elucidated the potential synergistic effects of DNA methyltransferases inhibitors (DNMTis) with iRT. Taken together, we outlined evidence suggesting that a combination of DNMTis, RT, and immunotherapy could be a promising treatment strategy to improve NSCLC outcomes.